Paradigm Biocapital Advisors LP Merus N.V. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Merus N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,369,699 shares of MRUS stock, worth $180 Million. This represents 7.27% of its overall portfolio holdings.
Number of Shares
3,369,699
Previous 1,689,922
99.4%
Holding current value
$180 Million
Previous $71.1 Million
99.59%
% of portfolio
7.27%
Previous 2.71%
Shares
7 transactions
Others Institutions Holding MRUS
# of Institutions
195Shares Held
62.2MCall Options Held
355KPut Options Held
96.5K-
Wellington Management Group LLP Boston, MA4.72MShares$251 Million0.04% of portfolio
-
Commodore Capital LP New York, NY4.47MShares$238 Million18.43% of portfolio
-
Rtw Investments, LP New York, NY4.17MShares$222 Million2.88% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.17MShares$169 Million3.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$160 Million2.04% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.45B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...